50-kHz ultrasonic vocalizations emitted by male rats during a 5-min period before introduction of a female (precontact vocalizations [PVs]) were analyzed in the context of acquisition of sexual experience. Changes in the main copulatory parameters and their N-methyl-D-aspartate (NMDA) receptor dependence, the role of contact with either anestrous or estrous females, and conditioning to odor and background cues were also investigated. Mount latency (ML) and intromission latency (IL) decreased after the 1st copulatory session, but ejaculation latency (EL) changed significantly only starting from the 4th session onward. The number of PVs gradually increased during the first 3-4 sessions. Blocking of NMDA receptors affected PVs and EL but not ML or IL. After a 5-month break in copulatory sessions, ML remained unchanged, whereas EL increased and the number of PVs decreased significantly. PVs were most robustly elevated by contact with estrous females. Exposure to background cues resulted in a linear decrease in number of PVs during 10 subsequent sessions without exposure to a female. The results suggest that, in the course of acquisition of a sexual experience, PVs reflect a learning process that depends on a rewarding value of sociosexual contact.

Normal or dysfunctional sexual behavior seems to be an important indicator of health or disease. Many health disorders in male patients affect sexual activity by directly causing erectile dysfunction, affecting sexual motivation, or both. Clinical evidence indicates that many diseases strongly disrupt sexual motivation and sexual performance in patients with depression, addiction, diabetes mellitus and other metabolic disturbances with obesity and diet-related factors, kidney and liver failure, circadian rhythm disorders, sleep disturbances including obstructive sleep apnea syndrome, developmental and hormonal disorders, brain damages, cardiovascular diseases, and peripheral neuropathies. Preclinical studies of these conditions often require appropriate experimental paradigms, including animal models. Male sexual behavior and motivation have been intensively investigated over the last 80 years in animal rat model. Sexual motivation can be examined using such parameters as: anticipatory behavior and 50-kHz ultrasonic vocalizations reflecting the emotional state of rats, initiation of copulation, efficiency of copulation, or techniques of classical (pavlovian) and instrumental conditioning. In this review article, we analyze the behavioral parameters that describe the sexual motivation and sexual performance of male rats in the context of animal experimental models of human health disorders. Based on analysis of the parameters describing the heterogeneous and complex structure of sexual behavior in laboratory rodents, we propose an approach that is useful for delineating distinct mechanisms affecting sexual motivation and sexual performance in selected disease states and the efficacy of therapy in preclinical investigations.

Elevated expression of c-fos mRNA and/or its protein (c-Fos) has been repeatedly observed following activation of brain cells with various stimuli. As a consequence it has been proposed that elevated c-fos expression may serve as a marker of neuronal activation reflecting a predisposal to long-term changes in cell functioning (neuronal plasticity). In studies on copulatory behaviour of male animals, elevated Fos immunoreactivity (related most probably to c-Fos) has been used by many researchers as a tool to reveal functional neuroanatomy of the behaviour. They found that brain regions such as medial preoptic area (MPOA), bed nucleus of stria terminalis (BNST), medial amygdala (MeAm) and central tegmental field (CTF) are always activated in a copulation-dependent manner in various species (rats and hamsters were the most often studied in this regard). This paper reviews the data gathered in this field, and discusses them in the context of a role of elevated Fos expression in acquisition vs. performance of the sexual behaviour.

In the last three decades, there has been a considerable improvement in human immunodeficiency virus (HIV) therapy. Acquired immunodeficiency syndrome (AIDS) is no longer a common cause of death for people living with HIV (PLWH) in developed countries, and co-infections with hepatitis viruses can be effectively managed. However, metabolic syndrome and metabolic dysfunction-associated steatotic liver disease (MASLD) are emerging threats these days, especially as the HIV-positive population gets older. The factors for MASLD development in PLWH are numerous, including non-specific (common for both HIV-positive and negative) and virus-specific. We focus on what is known for both, and in particular, on the burden of antiretroviral therapy (ART) for metabolic health and liver damage. We review data on contemporary drugs, including different groups and some particular agents in those groups. Among current ART regimens, the switch from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide fumarate (TAF) and particularly its combination with integrase inhibitors (INSTIs) appear to have the most significant impact on metabolic disturbances by increasing insulin resistance, which over the years promotes the evolution of the cascade leading to metabolic syndrome (MetS), MASLD, and eventually metabolic dysfunction-associated steatohepatitis (MASH).